Application of parallel artificial membrane permeability assay technique and chemometric modeling for blood–brain barrier permeability prediction of protein kinase inhibitors

References

• Thomsen MS, Humle N, Hede E, Moos T, Burkhart A, Thomsen LB. The blood-brain barrier studied in vitro across species. PLOS ONE 16(3), e0236770 (2021).
   PubMed Web of Science ®Google Scholar
• Abbott NJ, Patabendige AAK, Dolman DEM, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol. Dis. 37(1), 13–25 (2010).
   PubMed Web of Science ®Google Scholar
• Bicker J, Alves G, Fortuna A, Falcão A. Blood-brain barrier models and their relevance for a successful development of CNS drug delivery systems: a review. Eur. J. Pharm. Biopharm. 87(3), 409–432 (2014).
   PubMed Web of Science ®Google Scholar
• Nielsen PA, Andersson O, Hansen SH, Simonsen KB, Andersson G. Models for predicting blood-brain barrier permeation. Drug Discov. Today 16(11–12), 472–475 (2011).
   PubMed Web of Science ®Google Scholar
• Ardito F, Giuliani M, Perrone D, Troiano G, Lo Muzio L. The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review). Int. J. Mol. Med. 40(2), 271–280 (2017).
   PubMed Web of Science ®Google Scholar
• Theivendren P, Kunjiappan S, Hegde YM et al. Importance of protein kinase and its inhibitor: a review. 24, 75–100 (2021).
   Google Scholar
• Roskoski R. Properties of FDA-approved small molecule protein kinase inhibitors: a 2023 update. Pharmacol. Res. 187, 106552 (2023).
   PubMed Web of Science ®Google Scholar
• Carles F, Bourg S, Meyer C, Bonnet P. PKIDB: a curated, annotated and updated database of protein kinase inhibitors in clinical trials. Molecules 23(4), 1–18 (2018).
   Web of Science ®Google Scholar
• Liu DZ, Ander BP. Cell cycle inhibition without disruption of neurogenesis is a strategy for treatment of aberrant cell cycle diseases: an update. ScientificWorldJournal 2012, 491737 (2012).
   PubMedGoogle Scholar
• Lui A, Vanleuven J, Perekopskiy D et al. FDA-approved kinase inhibitors in preclinical and clinical trials for neurological disorders. Pharmaceuticals 15(12), (2022).
   Web of Science ®Google Scholar
• Conde-Estévez D. Targeted cancer therapy: interactions with other medicines. Clin. Transl. Oncol. 19(1), 21–30 (2017).
   PubMed Web of Science ®Google Scholar
• Heffron TP. Small molecule kinase inhibitors for the treatment of brain cancer. J. Med. Chem. 59(22), 10030–10066 (2016).
   PubMed Web of Science ®Google Scholar
• Chico LK, Van Eldik LJ, Watterson DM. Targeting protein kinases in central nervous system disorders. Nat. Rev. Drug Discov. 8(11), 892–909 (2009).
   PubMed Web of Science ®Google Scholar
• Pavlovic V, Petkovic M, Popovic S, Savic V. Synthesis of 4-Aryl-2-aminopyridine derivatives and related compounds. Inter. J. Rapid Commun. Synth. Organ. Chem. 39(23), 4249–4263 (2009).
   Google Scholar
• Filipović NR, Elshaflu H, Grubišić S et al. Co(III) complexes of (1,3-selenazol-2-yl)hydrazones and their sulphur analogues. Dalt. Trans. 46(9), 2910–2924 (2017).
   PubMed Web of Science ®Google Scholar
• Elshaflu H, Todorović TR, Nikolić M et al. Selenazolyl-hydrazones as novel selective MAO inhibitors with antiproliferative and antioxidant activities: experimental and in-silico studies. Front. Chem. 6(7), 369118 (2018).
   Google Scholar
• Kansy M, Senner F, Gubernator K. Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. J. Med. Chem. 41(7), 1007–1010 (1998).
   PubMed Web of Science ®Google Scholar
• Avdeef A. The rise of PAMPA. Expert Opin. Drug Metab. Toxicol. 1(2), 325–342 (2005).
   PubMedGoogle Scholar
• Di L, Kerns EH, Fan K, McConnell OJ, Carter GT. High throughput artificial membrane permeability assay for blood-brain barrier. Eur. J. Med. Chem. 38(3), 223–232 (2003).
   PubMed Web of Science ®Google Scholar
• Kato R, Zeng W, Siramshetty VB et al. Development and validation of PAMPA-BBB QSAR model to predict brain penetration potential of novel drug candidates. Front. Pharmacol. 14, 1291246 (2023).
   PubMed Web of Science ®Google Scholar
• Cornelissen FMG, Markert G, Deutsch G et al. Explaining blood-brain barrier permeability of small molecules by integrated analysis of different transport mechanisms. J. Med. Chem. 66(11), 7253–7267 (2023).
   PubMed Web of Science ®Google Scholar
• Sun H, Nguyen K, Kerns E et al. Highly predictive and interpretable models for PAMPA permeability. Bioorg. Med. Chem. 25(3), 1266–1276 (2017).
   PubMed Web of Science ®Google Scholar
• Niazi SK, Mariam Z. Recent advances in machine-learning-based chemoinformatics: a comprehensive review. Int. J. Mol. Sci. 24(14), 11488 (2023).
   PubMed Web of Science ®Google Scholar
• Liu H, Sabus C, Carter GT, Du C, Avdeef A, Tischler M. In vitro permeability of poorly aqueous soluble compounds using different solubilizers in the PAMPA assay with liquid chromatography/mass spectrometry detection. Pharm. Res. 20(11), 1820–1826 (2003).
   PubMed Web of Science ®Google Scholar
• Wishart DS, Knox C, Guo AC et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 34(Database issue), D668–D672 (2006).
   PubMed Web of Science ®Google Scholar
• Sander T, Freyss J, Von Korff M, Rufener C. DataWarrior: an open-source program for chemistry aware data visualization and analysis. J. Chem. Inf. Model 55(2), 460–473 (2015).
   PubMed Web of Science ®Google Scholar
• Frisch MJ, Trucks GW, Schlegel HB et al. Gaussian 09 (2009). https://gaussian.com/
   Google Scholar
• Talete S.R.L. DRAGON for Windows (Software for Molecular Descriptor Calculations) version 6.5 (2011). www.talete.mi.it/
   Google Scholar
• Simulation Plus Inc. ADMET Predictor version 9.5. (2019). www.simulations-plus.com/
   Google Scholar
• StatSoft Inc. Statistica, Data Analysis Software System. version 13.6 (2019). www.statistica.com/
   Google Scholar
• Ojha PK, Roy K. Comparative QSARs for antimalarial endochins: importance of descriptor-thinning and noise reduction prior to feature selection. Chemom. Intell. Lab. Syst. 109(2), 146–161 (2011).
   Web of Science ®Google Scholar
• Ojha PK, Mitra I, Das RN, Roy K. Further exploring rm2 metrics for validation of QSPR models. Chemom. Intell. Lab. Syst. 107(1), 194–205 (2011).
   Web of Science ®Google Scholar
• Chirico N, Gramatica P. Real external predictivity of QSAR models: how to evaluate It? Comparison of different validation criteria and proposal of using the concordance correlation coefficient. J. Chem. Inf. Model. 51(9), 2320–2335 (2011).
   PubMed Web of Science ®Google Scholar
• Guidance Document on the Validation of (Quantitative) Structure-Activity Relationship [(Q)SAR] Models (2014). www.oecd-ilibrary.org/environment/guidance-document-on-the-validation-of-quantitative-structure-activity-relationship-q-sar-models_9789264085442-en
   Google Scholar
• Roy K, Kar S, Das RN. Statistical Methods in QSAR/QSPR. A Primer on QSAR/QSPR Modeling: Fundamental Concepts. 37–59 (2015).
   Google Scholar
• SPSS Inc. PASW Statistics for Windows. Version 18.0. SPSS Inc., IL, USA (2009).
   Google Scholar
• van Vliet EF, Knol MJ, Schiffelers RM, Caiazzo M, Fens MHAM. Levodopa-loaded nanoparticles for the treatment of Parkinson's disease. J. Control. Rel. 360, 212–224 (2023).
   PubMed Web of Science ®Google Scholar
• Sekhar GN, Fleckney AL, Boyanova ST et al. Region-specific blood-brain barrier transporter changes leads to increased sensitivity to amisulpride in Alzheimer's disease. bioRxiv 582387 (2019).
   Google Scholar
• Bennion BJ, Be NA, McNerney MW et al. Predicting a drug's membrane permeability: a computational model validated with in vitro permeability assay data. J. Phys Chem. B 121(20), 5228–5237 (2017).
   PubMed Web of Science ®Google Scholar
• Peddi PF, Hurvitz SA. PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancer. J. Neurooncol. 117(1), 7 (2014).
   PubMed Web of Science ®Google Scholar
• Wang Q, Song LJ, Bin Ding Z et al. Advantages of Rho-associated kinases and their inhibitor fasudil for the treatment of neurodegenerative diseases. Neural Regen. Res. 17(12), 2623–2631 (2022).
   PubMed Web of Science ®Google Scholar
• Sato K, Nakagawa S, Morofuji Y et al. Effects of fasudil on blood-brain barrier integrity. Fluid. Barr. CNS 19(1), doi: 10.1186/s12987-022-00336-w (2022).
   PubMed Web of Science ®Google Scholar
• Leprieur EG, Fallet V, Cadranel J, Wislez M. Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives. Lung Cancer Targets Ther. 7, 83 (2016).
   PubMedGoogle Scholar
• Di L, Kerns EH. Passive Diffusion Permeability of the BBB-Examples and SAR. Blood-brain barrier in drug discovery: optimizing brain exposure of CNS drugs and minimizing brain side effects for peripheral drugs. John Wiley & Sons, Inc, NJ, USA 95–112 (2015).
   Google Scholar
• Todeschini R, Consonni V. S. Molecular Descriptors for Chemoinformatics. Wiley‐VCH Verlag GmbH & Co. KGaA, Weinheim, Germany 659–798 (2009).
   Google Scholar
• Zhang L, Zhu H, Oprea TI, Golbraikh A, Tropsha A. QSAR modeling of the blood-brain barrier permeability for diverse organic compounds. Pharm. Res. 25(8), 1902–1914 (2008).
   PubMed Web of Science ®Google Scholar
• Barn D, Caulfield W, Cowley P et al. Design and synthesis of a maximally diverse and druglike screening library using REM resin methodology. J. Comb. Chem. 3(6), 534–541 (2001).
   PubMedGoogle Scholar
• Wager TT, Hou X, Verhoest PR, Villalobos A. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. ACS Chem. Neurosci. 1(6), 435–449 (2010).
   PubMed Web of Science ®Google Scholar